Product Description
A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31793336/)
Mechanisms of Action: XPO1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - MyelofibrosisOrphan Drug - Myelofibrosis *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Hungary | Iceland | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Netherlands | Poland | Portugal | Singapore | Slovakia | Sweden | Taiwan | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Karyopharm
Company Location: NEWTON MA 02459
Company CEO: Richard Paulson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Bulgaria, Canada, China, Czech Republic, Denmark, Estonia, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Korea, Netherlands, Norway, Poland, Romania, Slovakia, Spain, United States
Active Clinical Trial Count: 51
Highest Development Phases
Phase 3: Acute Myeloid Leukemia|Anemia|Diffuse Large B-Cell Lymphoma|Endometrial Cancer|Multiple Myeloma|Myelofibrosis
Phase 2: Colorectal Cancer|Gastrointestinal Stromal Tumors|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Non-Small-Cell Lung Cancer|Ovarian Cancer|Polycythemia Vera|Primary Central Nervous System Lymphoma|T-Cell Peripheral Lymphoma|Thrombocythemia, Essential|Thrombocytopenia|Thrombocytosis|Thymoma|Transitional Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT05983276 | P2 |
Recruiting |
Ovarian Cancer |
2030-08-28 |
|
| XPORT-MF-044 | P2 |
Unknown Status |
Myelofibrosis|Thrombocytopenia |
2028-11-30 |
|
| XPORT-MF-034 | P3 |
Unknown Status |
Myelofibrosis|Anemia |
2028-08-31 |
|
| XPORT-MM-028 | P2 |
Unknown Status |
Multiple Myeloma |
2028-01-31 |